Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).
Bausch Health raises its 2026 revenue, EBITDA and cash flow outlook on strong Q3 results, while flagging Xifaxan pricing risks and inventory headwinds ahead
Bausch Health stock surged 26% after Q3 results, following a raised outlook and a first $1B EBITDA quarter. Here is what drove the rally and what could slow it next. The post What in the World Happened With Bausch Health Stock Last Week? appeared first on The Motley Fool Canada.
Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.
Bausch Health Companies Inc. (T.BHC) Hit a 52-Week High of $11.89. Wednesday, Bausch came out with quarterly ...
Today announced the publication of results from a multinational survey examining symptoms, interactions ...
Bausch (BHC) delivered earnings and revenue surprises of +63.89% and +7.11%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
QUEBEC, Quebec (AP) — QUEBEC, Quebec (AP) — Bausch Health Companies Inc. (BHC) on Wednesday reported third-quarter net income of $436 million.
Detailed price information for Bausch Health Companies Inc (BHC-T) from The Globe and Mail including charting and trades.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter.
Dan Loeb’s Third Point acquired approximately 85,000 Bausch + Lomb shares worth about $1.4 million as of June 30, according to the filing.
Detailed price information for Bausch Health Companies Inc (BHC-T) from The Globe and Mail including charting and trades.
Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Detailed price information for The Chefs Warehouse (CHEF-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.